Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease

Buruli ulcer, caused by infection with Mycobacterium ulcerans , is a necrotizing disease of the skin and subcutaneous tissue, which is most prevalent in rural regions of West African countries. The majority of clinical presentations seen in patients are ulcers on limbs that can be treated by eight weeks of antibiotic therapy. Nevertheless, scarring and permanent disabilities occur frequently and Buruli ulcer still causes high morbidity. A vaccine against the disease is so far not available but would be of great benefit if used for prophylaxis as well as therapy. In the present study, vesicular stomatitis virus-based RNA replicon particles encoding the M . ulcerans proteins MUL2232 and MUL3720 were generated and the expression of the recombinant antigens characterized in vitro . Immunisation of mice with the recombinant replicon particles elicited antibodies that reacted with the endogenous antigens of M . ulcerans cells. A prime-boost immunization regimen with MUL2232-recombinant replicon particles and recombinant MUL2232 protein induced a strong immune response but only slightly reduced bacterial multiplication in a mouse model of M . ulcerans infection. We conclude that a monovalent vaccine based on the MUL2232 antigen will probably not sufficiently control M . ulcerans infection in humans.